Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026193 | 1.00 | MEN1 (0.57) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4023412 | 0.92 | MEN1 (0.48) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4021266 | 0.90 | MEN1 (0.49) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL6954031 | 0.90 | MEN1 (0.48) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL6954036 | 0.90 | MEN1 (0.48) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4022442 | 0.88 | MEN1 (0.61) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4022774 | 0.88 | MEN1 (0.61) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4027455 | 0.80 | LPAR1 (0.43) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL4030676 | 0.80 | TACR1 (0.48) | CTSLCTSBCTSSCTSK | |
| SCHEMBL4027452 | 0.80 | LPAR1 (0.43) | MEN1KMT2ACTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171428-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-06-17 | — | — | EP | disclosed |
| EP-1171428-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | disclosed |
| US-20030139377-A1 | Fab I inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
| EP-1171428-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063187-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139377-A1 | Fab I inhibitors | SERPINB1, TFPI, TFPI2 | MEN1 3548/4885KMT2A 4421/4885CTSL 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.